Cargando…

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia

OBJECTIVE: Chronic myeloid leukemia (CML) is a disease caused by the acquisition of BCR-ABL1 fusion in hematopoietic stem cells. In this study, we focus on the oncofetal ENOX2 protein as a potential secretable biomarker in CML. MATERIALS AND METHODS: We used cell culture, western blot, quantitative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baykal, Seda, Voldoire, Maud, Desterke, Christophe, Sorel, Nathalie, Cayssials, Emilie, Johnson-Ansah, Hyacinthe, Guerci-Bresler, Agnes, Bennaceur-Griscelli, Annelise, Chomel, Jean-Claude, Turhan, Ali G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240159/ https://www.ncbi.nlm.nih.gov/pubmed/37026766 http://dx.doi.org/10.4274/tjh.galenos.2023.2022-0339

Ejemplares similares

Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with BCR::ABL1 from Chronic Myeloid Leukemia (CML) in Blast Crisis
por: Boucher, Lara, et al.
Publicado: (2023)

Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors
por: Aggoune, Djamel, et al.
Publicado: (2014)

Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML)
por: Gentil, Melanie, et al.
Publicado: (2018)

PPARγ Cistrome Repression during Activation of Lung Monocyte-Macrophages in Severe COVID-19
por: Desterke, Christophe, et al.
Publicado: (2020)

HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease
por: Desterke, Christophe, et al.
Publicado: (2021)

EGR1 dysregulation defines an inflammatory and leukemic program in cell trajectory of human-aged hematopoietic stem cells (HSC)
por: Desterke, Christophe, et al.
Publicado: (2021)

Modeling Blast Crisis Using Mutagenized Chronic Myeloid Leukemia-Derived Induced Pluripotent Stem Cells (iPSCs)
por: Imeri, Jusuf, et al.
Publicado: (2023)

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation
por: Chomel, Jean Claude, et al.
Publicado: (2016)

Detection of Hematopoietic Stem Cell Transcriptome in Human Fetal Kidneys and Kidney Organoids Derived From Human Induced Pluripotent Stem Cells
por: Hwang, Jin Wook, et al.
Publicado: (2021)

Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells
por: Flamant, Stéphane, et al.
Publicado: (2019)

Embryonic Program Activated during Blast Crisis of Chronic Myelogenous Leukemia (CML) Implicates a TCF7L2 and MYC Cooperative Chromatin Binding
por: Desterke, Christophe, et al.
Publicado: (2020)

Genomic landscape analyses of reprogrammed cells using integrative and non-integrative methods reveal variable cancer-associated alterations
por: Griscelli, Frank, et al.
Publicado: (2019)

Molecular investigation of adequate sources of mesenchymal stem cells for cell therapy of COVID‐19‐associated organ failure
por: Desterke, Christophe, et al.
Publicado: (2020)

Evidence of Antitumor and Antimetastatic Potential of Induced Pluripotent Stem Cell-Based Vaccines in Cancer Immunotherapy
por: Kishi, Masae, et al.
Publicado: (2021)

iPSC-Derived Organoids as Therapeutic Models in Regenerative Medicine and Oncology
por: Turhan, Ali G., et al.
Publicado: (2021)

iPSC-Derived Hereditary Breast Cancer Model Reveals the BRCA1-Deleted Tumor Niche as a New Culprit in Disease Progression
por: Portier, Lucie, et al.
Publicado: (2021)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Case report: Long-term voluntary Tyrosine Kinase Inhibitor (TKI) discontinuation in chronic myeloid leukemia (CML): Molecular evidence of an immune surveillance
por: Imeri, Jusuf, et al.
Publicado: (2023)

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study
por: Foulon, Stéphanie, et al.
Publicado: (2019)

iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma
por: Hwang, Jin Wook, et al.
Publicado: (2019)

Modeling Global Genomic Instability in Chronic Myeloid Leukemia (CML) Using Patient-Derived Induced Pluripotent Stem Cells (iPSCs)
por: Telliam, Gladys, et al.
Publicado: (2023)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

ENOX2 Target for the Anticancer Isoflavone ME-143
por: Morré, D. James, et al.
Publicado: (2014)

Clinically silent indolent T‐cell leukemia
por: Janot, Clément, et al.
Publicado: (2018)

A mesenchymal glioma stem cell profile is related to clinical outcome
por: Balbous, A, et al.
Publicado: (2014)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Patient-Derived iPSCs Reveal Evidence of Telomere Instability and DNA Repair Deficiency in Coats Plus Syndrome
por: Oudrhiri, Noufissa, et al.
Publicado: (2022)

Targeting Enox1 in tumor stroma increases the efficacy of fractionated radiotherapy
por: Smith, Clayton A., et al.
Publicado: (2016)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
por: Hughes, T P, et al.
Publicado: (2017)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Genomic instability of human embryonic stem cell lines using different passaging culture methods
por: Tosca, Lucie, et al.
Publicado: (2015)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Morphological Analysis of Human Induced Pluripotent Stem Cells During Induced Differentiation and Reverse Programming
por: Courtot, Anne-Marie, et al.
Publicado: (2014)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_84ohjkte94d3kgs3bucgcb1oir